Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 12/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.47 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.47 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.47 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475475 | 0.82 | CYP3A4 (0.57) | CYP1A2CYP3A4CYP2C9CYP1A1CYP1B1 | |
| SCHEMBL4581721 | 0.81 | CYP11B1 (0.58) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12108683 | 0.80 | CYP11B1 (0.65) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL12302844 | 0.80 | CYP11B1 (0.65) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20470430 | 0.80 | CYP11B2 (0.57) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL981006 | 0.80 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29431754 | 0.80 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5702666 | 0.80 | CYP1A1 (0.74) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15394522 | 0.78 | KIF11 (0.54) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15340942 | 0.78 | CYP11B2 (0.54) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | claimed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | CYP11B1 4619/4885CYP11B2 4742/4885CYP1A2 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.